Saturday, October 31, 2026

Align Technology Stock Soars Over 12% In Thursday Trading

ViaNews Editorial Team

December 15, 2023

Align Technology Stock Soars Over 12% In Thursday Trading

(VIANEWS) - Align Technology Shares Rally Over 12 % on NASDAQ, Reach 52-Week High Align Technology (NASDAQ: ALGN) stock saw an outstanding 12.62% surge to EUR260.55 at 21:24 EST on Thursday evening, continuing its upward trajectory and helping propel NASDAQ overall uptick of 0.35% to EUR14,784.95, marking its sixth straight day of gains. Align Technology's stock price recently surged 44.01% lower than its 52-week high of EUR413.20 due to investor trust being instilled through their success on the market and increased demand for their shares. Investors eagerly anticipate updates on the company's progress as it innovates and expands in the orthodontic and dental industries.

About Align Technology

Align Technology is a world leader in orthodontic and dental technology, producing and marketing Invisalign clear aligners and iTero intraoral scanners as well as providing services to orthodontists and general practitioner dentists around the world. Our company operates two business segments, Clear Aligner and Imaging Systems as well as CAD/CAM Services (Systems and Services). Clear Aligner offers comprehensive and non-comprehensive products designed specifically to address teenage and younger patient needs, along with retention products, Invisalign training courses, and tools used by dental professionals during treatment. Align Technology was founded in 1997 and currently maintains its headquarters in Tempe, Arizona. Their Systems and Services segment offers the iTero intraoral scanning system, restorative software, orthodontic diagnosis software, TimeLapse technology, subscription software licenses, disposables rentals leases leases pay per scan services among many other offerings.

Yearly Analysis

Align Technology's stock is currently trading at EUR260.55, significantly below its 52-week high of EUR413.20 but higher than its 52-week low of EUR176.34 - suggesting a period of heightened volatility over the last year. Align Technology is projected to experience sales growth of 2.6% this year and 5.3% next year, signaling an expected moderate pace of revenue expansion over time. Align Technology's EBITDA figure stands at 4.15, providing insight into its profitability. This indicates that Align is producing positive earnings before accounting for interest, taxes, depreciation and amortization expenses. Align Technology appears to be a moderate investment choice with potential for expansion of sales and profitability. Investors should carefully consider their own investment goals and risk tolerance prior to making any decisions about Align Tech investments.

Technical Analysis

Align Technology stock has experienced an erratic ride recently, and currently sits above its 50-day moving average of EUR232.45 but significantly below its 200-day moving average of EUR341.75.

Quarter Analysis

Align Technology, a leading provider of orthodontic and dental treatments, has experienced sustained sales growth over the past year. Current quarter sales growth stands at 3.7% with only minor adjustments expected in future quarters (a decrease of 0.1% is anticipated). Even though growth estimates for current quarter stand at 26% and 13.2% for subsequent ones respectively. Align Technology's ambitious growth projections reflect its impressive market performance and ability to seize emerging opportunities. Over the last twelve months, quarterly revenue grew at 7.8% year-on-year bringing current total revenue up to $3.81B. Investors should take notice of Align Technology's positive trends and growth projections, which indicate a bright future outlook. At the same time, external factors like market competition or regulatory changes that might inhibit its potential should also be taken into consideration. Overall, Align Technology appears to be an excellent investment option for capitalizing on the expansion of dental and orthodontic industries.

Equity Analysis

Align Technology is a company which designs, produces and markets Invisalign clear aligners and iTero intraoral scanning systems. Their trailing twelve months EPS stands at EUR4.72 which indicates profitability. The company's trailing twelve months price to earnings ratio stands at 55.2, which indicates high expectations of future earnings growth from investors. ROE of 9.68% indicates a company's profitability relative to shareholder's equity. An ROE of this size is considered average within its industry. Align Technology is an attractive company with high earnings growth expectations as evidenced by its high PE ratio, yet only average returns on equity compared to its industry peers. Investors should keep these factors in mind and conduct independent research before making investment decisions.

More news about Align Technology (ALGN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com